New MS injection for kids enters testing
NCT ID NCT07503340
Summary
This study is testing a new under-the-skin injection version of the MS drug ocrelizumab in children and teenagers aged 10 to 18. The main goals are to see how the drug moves through the body, if it's safe, and how it affects the immune system. Participants will receive the drug for at least 48 weeks, with long-term safety monitoring.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.